|
rs2735839
|
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
No association was observed between the polymorphism A>G of rs2735839 and risk of PCa.
|
30413614 |
2018 |
|
rs2735839
|
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Our results provide further support that a PC-risk SNP rs2735839 near the KLK3 gene on chromosome 19q13 may be associated with aggressive and high-grade PC.
|
25715684 |
2015 |
|
rs2735839
|
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We confirmed the association of the rs2735839 with high-aggressive prostate cancer (GS ≥8).
|
25274378 |
2014 |
|
rs2735839
|
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The reported risk allele (G) for single nucleotide polymorphism rs2735839 in the KLK3 gene at 19q13 was more frequent in less aggressive prostate cancer patients (0.89) than in more aggressive prostate cancer patients (0.86; nominal P = 0.03) or in controls (0.86; nominal P = 0.04).
|
18794092 |
2008 |
|
rs2735839
|
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
In summary, rs752822 and rs2735839 may assist in risk-stratifying GS 7 patients and predict prostate cancer reclassification.
|
27515962 |
2016 |
|
rs2735839
|
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Two SNPs, rs2735839 at chromosome 19q13 and rs7679673 at 4q24, were associated with prostate cancer-specific survival (P = 7 × 10(-4) and 0.014, respectively).
|
21367958 |
2011 |
|
rs2735839
|
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
For the two SNPs that had significant differences between more and less aggressive disease rs2735839 in KLK3 (P = 8.4 x 10(-7)) and rs10993994 in MSMB (P = 0.046), the alleles that are associated with increased risk for PCa were more frequent in patients with less aggressive disease.
|
19434657 |
2009 |
|
rs2735839
|
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The rs61752561 in KLK3 and rs2735839 in the KLK2-KLK3 intergenic region were strongly associated with prostate cancer-specific survival, and rs10486567 in the 7JAZF1 gene were associated with biochemical recurrence.
|
20460480 |
2010 |
|
rs2735839
|
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
When comparing prostate cancer cases with low PSA controls, alleles at genetic markers rs1512268, rs445114, rs10788160, rs11199874, rs17632542, rs266849, and rs2735839 were associated with an increased risk of prostate cancer, but the effect-estimates were attenuated to the null when using high PSA controls (Pheterogeneity in effect-estimates < 0.04).
|
24753544 |
2014 |
|
rs2735839
|
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Four GWAS replication SNPs (rs2660753, rs13254738, rs10090154, rs2735839) and seven flanking SNPs were associated with CaP aggressiveness (P < 0.05) in three genomic regions: One at 3p12 (EA), seven at 8q24 (5 AA, 2 EA), and three at 19q13 at the kallilkrein-related peptidase 3 (KLK3) locus (two AA, one AA and EA).
|
22549899 |
2013 |
|
rs2735839
|
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Higher levels of PSA in the presence of KLK3 polymorphism in patients with PC indicated that rs2735839 polymorphism could be a risk factor for increased levels of PSA.
|
31017705 |
2019 |
|
rs2735839
|
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We did not observe a strong association with the KLK3 variant, reported in previous studies to confer risk for prostate cancer (rs2735839; P = 0.20) but did observe three highly correlated SNPs (rs17632542, rs62113212 and rs62113214) associated with prostate cancer [P = 3.41 × 10(-4), per-allele trend odds ratio (OR) = 0.77, 95% CI = 0.67-0.89].
|
21318478 |
2011 |
|
rs4242382
|
|
Prostate carcinoma
|
|
0.740 |
GeneticVariation
|
BEFREE |
Two correlated SNPs--rs10090154 and rs4242382--in Region 1 of chromosome 8q24, a prostate cancer susceptibility region, demonstrated statistically significant associations with colorectal cancer risk.
|
23935004 |
2014 |
|
rs4242382
|
|
Prostate carcinoma
|
|
0.740 |
GeneticVariation
|
BEFREE |
The ORs for a previously identified variant, rs4242382, and prostate cancer increased significantly (P<0.05) with exposure to the organophosphate insecticide fonofos, after correction for multiple testing, with per allele ORnonexposed of 1.17 (95% CI, 0.93-1.48), per allele OR(low) of 1.30 (95% CI, 0.75-2.27), and per allele ORhigh of 4.46 (95% CI, 2.17-9.17; P-interaction=0.002, adjusted P-interaction=0.02).
|
20978189 |
2010 |
|
rs4242382
|
|
Prostate carcinoma
|
|
0.740 |
GeneticVariation
|
BEFREE |
Blood samples from Finnish men were used to assess the risk of PCa related to three genetic variants (rs4242382, rs138213197, and rs200331695).
|
25683204 |
2015 |
|
rs4242382
|
|
Prostate carcinoma
|
|
0.740 |
GeneticVariation
|
BEFREE |
The replicated data suggest that the 8q24 rs4242382-A variation might be associated with increased PCa susceptibility in Asian, Caucasian and African American populations.
|
25339022 |
2014 |
|
rs5945572
|
|
Prostate carcinoma
|
|
0.730 |
GeneticVariation
|
BEFREE |
Two newly identified variants were shown to be associated with prostate cancer: rs5945572 on Xp11.22 and rs721048 on 2p15 (odds ratios (OR) = 1.23 and 1.15; P = 3.9 x 10(-13) and 7.7 x 10(-9), respectively).
|
18264098 |
2008 |
|
rs5945572
|
|
Prostate carcinoma
|
|
0.730 |
GeneticVariation
|
BEFREE |
Five SNPs showed independent associations with prostate cancer progression (rs12621278, rs629242, rs9364554, rs4430796, and rs5945572) based on stepwise regression analysis.
|
20651075 |
2010 |
|
rs5945572
|
|
Prostate carcinoma
|
|
0.730 |
GeneticVariation
|
BEFREE |
Two single nucleotide polymorphisms (SNP; rs5945572 and rs5945619) at Xp11 were recently implicated in two genome-wide association studies of prostate cancer.
|
19549809 |
2009 |
|
rs103294
|
|
Prostate carcinoma
|
|
0.730 |
GeneticVariation
|
BEFREE |
In addition to confirming several associations reported in other ancestry groups, this study identified two new risk-associated loci for prostate cancer on chromosomes 9q31.2 (rs817826, P = 5.45 × 10(-14)) and 19q13.4 (rs103294, P = 5.34 × 10(-16)) in 4,484 prostate cancer cases and 8,934 controls.
|
23023329 |
2012 |
|
rs103294
|
|
Prostate carcinoma
|
|
0.730 |
GeneticVariation
|
BEFREE |
A recent prostate cancer (PCa) genome-wide association study (GWAS) identified rs103294, a single nucleotide polymorphism (SNP) located on LILRA3, a key component in the regulation of inflammatory inhibition, to be significantly associated with PCa risk in a Chinese population.
|
23615473 |
2013 |
|
rs103294
|
|
Prostate carcinoma
|
|
0.730 |
GeneticVariation
|
BEFREE |
Three SNPs-rs2735839, rs10486567, and rs103294-were associated with biopsy-proven high-aggressive (GS ≥8) prostate cancer (P < 0.05).
|
25274378 |
2014 |
|
rs7679673
|
|
Prostate carcinoma
|
|
0.720 |
GeneticVariation
|
BEFREE |
Two SNPs, rs2735839 at chromosome 19q13 and rs7679673 at 4q24, were associated with prostate cancer-specific survival (P = 7 × 10(-4) and 0.014, respectively).
|
21367958 |
2011 |
|
rs7679673
|
|
Prostate carcinoma
|
|
0.720 |
GeneticVariation
|
BEFREE |
SNP rs7679673, ~6.3kb upstream of TET2 and previously reported to be associated with prostate cancer risk, was associated with endometrial cancer risk in the direction opposite to that for prostate cancer [meta-analysis odds ratio = 0.87 (per copy of the C allele), 95% confidence interval = 0.81, 0.93; P = 7.37×10(-5)] with no evidence of heterogeneity across studies (P heterogeneity = 0.66).
|
24832084 |
2014 |
|
rs11986220
|
|
Prostate carcinoma
|
|
0.720 |
GeneticVariation
|
BEFREE |
Two enhancers in one risk region were occupied by AR and responded to androgen treatment; one contained a single nucleotide polymorphism (rs11986220) that resides within a FoxA1 binding site, with the prostate cancer risk allele facilitating both stronger FoxA1 binding and stronger androgen responsiveness.
|
19680443 |
2009 |